Bacteria and yeasts in the treatment of acute and chronic infectious diarrhea. Part II: Yeasts

Clinical Microbiology and Infection

Volumn 5, Issue 7, 1999, Pages 389-395

  Vandenplas, Yvan ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Biotherapeutic agent; Diarrhea; Gastroenteritis; Probiotic; Saccharomyces boulardii yeast

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN;

ACUTE DIARRHEA; BACTERIUM; BINDING AFFINITY; CHRONIC DIARRHEA; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTERIC FEEDING; HUMAN; INTESTINE CELL; INTESTINE FLORA; LACTOBACILLUS; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SACCHAROMYCES BOULARDII; TRAVELLER DIARRHEA; YEAST;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; LACTOBACILLUS; SACCHAROMYCES BOULARDII;

EID: 0032868280     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00162.x     Document Type: Review

References (71)

1. Vandenplas Y. Bacteria and yeasts in the treatment of acute and chronic infectious diarrhoea. I. Bacteria. Clin Microbiol Infect 1999; 5: 299-307.
2. McFarland LV, Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis 1993; 6: 157-71.
3. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996; 275: 870-6.
4. World Health Organization. Saccharomyces boulardii: a valuable adjunct in recurrent Clostridium difficile disease? WHO Drug Information 1995; 9: 15-16.
5. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii in healthy human volunteers. Pharm Res 1993; 10: 1615-19.
6. Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharmaceut Drug Dispos 1989; 10: 353-64.
7. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90: 439-48.
8. Boddy AV, Elmer GW, McFarland LV, Levy RH. Influence of antibiotics on the recovery of Saaharomyces boulardii in rats. Pharm Res 1991; 8: 796-800.
9. Elmer G, Moyer K, Vega R, et al. Pharmacokmetic studies of Saccharomyces boulardii in patients with HIV-related chronic diarrhea in healthy volunteers. In: XIX International Congress on Microbial Ecology and Disease, Rome, 1994.
10. Machado Caetano JA, Parames MT, Babo MJ, et al. Immunopharmacological effects of Saccharomyces boulardii in healthy human volunteers. Int J Immunopharmacol 1986; 8: 245-59.
11. Nicod-Bertin L, Panouse-Perrin J. Propriétés activatrices de deux préparations de levures vis-à-vis du système complément humain. Rev Inst Pasteur Lyon 1985; 18: 345-65.
12. Brugier S, Patte F. Antagonisme in vitro entre Perenterol et différents germes bactériens. Med Paris 1975; 45: 3-8.
13. Bergogne-Bérézin E, Bornet M. In vitro antagonistic effect of Saccharomyces boulardii against bacteria involved in diarrhea in intensive-care-unit patient. Sci Alim 1986; 6: 63-73.
14. Rigothier MC, Maccario J, Gayral P. Inhibitory activity of Saccharomyces yeasts on the adhesion of Entamoeba histolytica trophozoites to human erythrocytes in vitro. Parasitol Res 1994; 80: 10-15.
15. Ducluzeau R, Bensaada M. Effet comparé de l'administration unique ou en continu de Saccharomyces boulardii sur l'établissement de diverses souches de Candida dans le tractus digestif de souris gnotoxéniques. Ann Microbiol 1982; 133: 491-501.
16. Berg R, Bernasconi P, Fowler D, Gautreux M. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis 1993; 168: 1314-18.
17. Massot J, Desconlois M, Patte F. Renforcement par un Saccharomyces de l'action antibiotique de la chlorotetracycline sur la Salmonellose experimentale de la souris. Bull Soc Mycol Med 1978; 7: 73-6.
18. Rodrigues ACP, Nardi RM. Bambirra EA, Vieira EC, Nicoli JR. Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella ftexneri in conventional and gnotobiotic mice. J Appl Bacteriol 1996; 81: 251-6.
19. Massot J, Desconclois M, Patte F. Effet protecteur d'un Saccharomyces lors d'une infection bactérienne chez la souris. Bull Soc Mycol Med 1977; 6: 45-8.
20. Rigothier MC, Maccario J, Vuong PN, Gayral Ph. Effets des levures Saccharomyces boulardii sur les trophozoïtes d'Entamoeba histolytica in vitro et dans l'amibiase caecale du jeune rat. Ann Parasitol Hum Comp 1990; 65: 51-60.
21. Czerucka D, Roux I, Rampal P. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 1994; 106: 65-72.
22. Dias RS, Bambirra EA, Silva ME, Nicoli JR. Protective effect of Saccharomyces boulardii against the cholera toxin in rats. Braz J Med Biol Res 1995; 28: 323-5.
23. Vidon N, Huchet B, Rambaud JC. Influence de Saccharomyces boulardii sur la sécrétion jéjunale induite chez le rat par la toxine cholérique. Gastroenterol Clin Biol 1986; 10: 13-16.
24. Massot J, Desconclois M, Astoin J. Protection par Saccharomyces boulardii de la diarrhée à Eschcrichia coli du souriceau. Ann Pharm France 1982; 40: 445-9.
25. Czerucka D, Rampal P. L'effet protecteur de Saccharomyces boulardii sur Escherichia coli entérotoxinogènes (ECET) et entéropathogènes (ECEP): étude in vitro. Med Chir Dig 1997; 26: 157-9.
26. Castagliuolo I, Lamont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996; 64: 5225-32.
27. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104: 1108-15.
28. Pothoulakis C. Mechanisms of Saccharomyces boulardii on Clostridium difficile infection. In: Rambaud J-C, LaMont JT. eds. Updates on Clostridium difficile, Paris, Springer Verlag 1996.
29. Massot J, Sanchez O, Couchy R, Astoin J, Parodi AL. Bacteriopharmacological activity of Saccharomyces boulardii in clindamycin-induced colitis in the hamster. Drug Res 1984; 34: 794-7.
30. Castex F, Corthier G, Jouvert S, Elmer GW, Lucas F, Bastide M. Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study. J Gen Microbiol 1990; 136: 1085-9.
31. Capano G, Bloch KJ, Carter EA, Dascoli JA, Schoenfeld D. Harmatz PR. Polyamines in human and rat milk influence intestinal cell growth in vitro. J Pediatr Gastroenterol Nutr 1998; 27: 281-6.
32. Tutton PJ, Barkla DH. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells. Anticancer Res 1987; 7: 1-12.
33. Buts JP, De Keyser N, Kolanowski J, Sokal E, Van Hoof F. Maturation of villus and crypt cell functions in rat small intestine: role of dietary polyamines. Dig Dis Sci 1993; 38: 1091-8.
34. Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R. Response of human and rat intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 1986; 20: 192-6.
35. Buts JP, Bernasconi P, Vaerman JP, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 1990; 35: 251-6.
36. Jahn HU, Ullrich R, Schneider T, et al. Immimological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion 1996; 57: 95-104.
37. Johnson LR, Brockway PD, Madsen K, Hardm JA, Grant Gall D. Polyamines alter intestinal glucose transport. Am J Physiol 1995; 31: G416-23.
38. Buts JP, De Keyser N, De Raedemaeker L. Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res 1994; 36: 552-7.
39. Vanderhoof JA, Kollman K, Goulet O. Saccharomyces boulardii does not stimulate mucosal hyperplasia following intestinal resection in the rat. J Pediatr Gastroenterol Nutr 1998; 26: 567.
40. Zaouche A, Loukil C, Peuchmaur M, et al. Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation and intestinal adaptation after small bowel resection in growing rats. J Pediatr Gastroenterol Nutr 1998; 26: 570.
41. Adam P. Essais cliniques controlés en double insu de l'ultra-levure lyophilisée (étude multicentrique par 25 médecins de 388 cas). Médecine et Chirurgie Digestive 1976; 5: 401-6.
42. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96: 981-8.
43. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease, JAMA 1994; 271: 1913-18.
44. Tempé JD, Steidel AL, Bléhaut H, Hasselman M, Lutun Ph, Maurier F. Prévention par Saccharomyces boulardii des diarrhées de l'alimentation entérale à débit continu. Semaine Hopit Paris 1983; 59: 1409-12.
45. Schlotterer M, Bernasconi P, Lebreton F, Wasserman D. Intérêt de Saccharomyces boulardii dans la tolérance digestive de la nutrition entérale à débit continu chez le brûlé. Nutr Clin Metab 1987; 1: 31-4.
46. Bleichner G, Bléhaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. Intensive Care Med 1997; 23: 517-23.
47. Kollaritsch HH, Kemsner P, Wiedermann G, Scheiner O. Prevention of traveller's diarrhoea. Comparison of different non-antibiotic preparations. Travel Med Int 1989; 9-17.
48. Czerucka D, Nano JL, Bernasconi P, Rampai P. Réponse aux toxines A et B de Clostridium difficile d'une lignée de cellules épithéliales intestinales de rat: IRD 9. Effet de Saccharomyces boulardii. Gastroenterol Clin Biol 1991; 15: 22-7.
49. Toothaker RD, Elmer GW. Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii. Antimicrob Agents Chemother 1984; 26: 552-6.
50. Surawicz CM, McFarland LV, Elmer GW, Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 1989; 84: 1285-7.
51. Kimmey MB, Elmer GW, Surawicz CM, McFarland LV. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci 1990; 35: 897-901.
52. Buts JP, Corthier G, Delmée M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 1993; 17: 419-25.
53. Höchter W, Chase D, Hagenhoff G. Saccharomyces boulardii in acute adult diarrhoea. Münch Med Wochenschr 1990; 132: 188-92.
54. Cetina-Sauri G, Sierra Basto G. Evaluation thérapeutique de Saccharomyces boulardii chez des enfants souffrant de diarrhée aiguë. Ann Pediatr 1994; 41: 397-400.
55. Chapoy P. Traitement des diarrhées aiguës infantiles: essais contrôlé de Saccharomyces boulardii. Ann Pediatr Paris 1985; 32: 561-3.
56. Jouirou A, Jeridi A, Ben Said H, El Mabrouk J, Essoussi AS, Harbi A. Le traitement des diarrhées aiguës du nourrisson: place de Saccharomyces boulardii. -Maghreb Med 1990; 229: 29-31.
57. Castaneda C. Effects of Saccharomyces boulardii in children with chronic diarrhea, especially due to giardiasis. Rev Mexicana Puericultura Pediatr 1995; 2.
58. Saint-Marc T, Bléhaut H, Musial Ch, Touraine JL. Diarrhöen im Zusammenhang mit AIDS (Doppelblindstudie mit Saccharomyces boulardii). Sem Hop Paris 1995; 71: 735-41.
59. Sadoun-Journo E, Gaillard JL, Beihaut H, Goulet O, Bernasconi P, Ricour C. Grêle court dysfonctionnel (GCD) compliqué de pullalation bactérienne cher l'enfant: effet de Saccharomyces boulartiii (SB). Gastroenterol Clin Biol. 1994; 18: 101.
60. Kirchelle A, Frühwein N, Toburen D. Behandlung der persistierenden Diarhöe mit S. boulardii bei Reiserückkehren. Fortschr Med 1996; 144: 136-40.
61. Plein J, Hotz J. Therapeutic effect of Saccharomyces boulardii on mild residual symptoms in astable phase of Crohn's disease with special respect to chronic diarrhea, a pilot study. Z Gastroenterol 1993; 31: 129-34.
62. Saint-Marc T, Rossello-Prats L, Touraine JL. Efficacité de Saccharomyces boulardii dans le traitement des diarrhées du SIDA. Ann Med Interne Paris 1991; 142: 64-5.
63. Grillot R, Lebeau B, Gouillier-Fleuret A, Chouraqui JP, Andrini P. De deux maux il faut choisir le moindre ou du caractere opportuniste de Saccharomyces boulardii. Résumé des Rapports. Société Française de Mycologie Médicale, 1986.
64. Zunic P, Lacotte J, Pegoix M, et al. Fongémie a Saccharomyces boulardii. Therapie 1991; 45: 497-501.
65. Forge G, Aznar C, Marguet F, Polomeni P, Bouchet R, Manicacci M. Saccharomyces fungemia in AIDS patients after treatment for chronic diarrhea. In: The Fifth European Conference on Clinical Aspects and Treatment of HIV Infection, Copenhagen, Denmark, 1995.
66. Pletincx M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 1995; 21: 113-15.
67. Viggiano M, Badetti C, Bernini V, Garabedian M, Manelli JC. Fongémie à Saccharomyces boulardii chez un brûlé grave. Ann Fr Anesth Reanim 1995; 14: 356-8.
68. Boucaud C, Berrada K, Bouletreau P. Septicémie à Saccharomyces boulardii après administration orale d'ultra-levure. Rean Urg 1996; 5: 665.
69. Piarroux R, Millon L, Bardonnet K, Vagner O, Koenig H. Are live Saccharomyces yeasts harmful to patients? Lancet 1999; 353: 1851-2.
70. Niault M, Thomas F, Prost J, Ansari Hojjat F, Kalfon P. Fungemia due to Saccharomyces species in a patient treated with enterai Saccharomyces boulardii CID 1999; 28: 930.
71. Vanderhoof JA, Young RJ. Use of probiotics in childhood gastrointestinal disorders. J Pediatr Gastroenterol Nutr 1998; 27: 323-32.